XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Share Capital (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 23, 2018
Mar. 07, 2018
Mar. 31, 2018
Share Capital [Line Items]      
Gain on termination of collaboration agreement   $ 4,398 $ 4,398
Teva Pharmaceuticals International GmbH and Teva Canada Limited [Member]      
Share Capital [Line Items]      
Collaborative development and license agreement termination date   Mar. 07, 2018  
Teva Canada Limited [Member]      
Share Capital [Line Items]      
Number of common shares agreed to transfer and assign for cancellation   1,000,000  
BVF Partners L.P [Member] | Exchange Agreement [Member]      
Share Capital [Line Items]      
Estimated weighted average cancellation price per share of common stock $ 7.61    
BVF Partners L.P [Member] | Exchange Agreement [Member] | Series1 Preferred Shares      
Share Capital [Line Items]      
Issued (cancelled) pursuant to exchange agreement 2,868,000    
Preferred shares convertible into common shares one-for-one    
Common shares issued on conversion of preferred stock 1    
Maximum beneficial ownership limitation percentage for conversion of common stock issued and outstanding 9.99%    
Maximum beneficial ownership limitation upon notice, percentage for conversion of common stock issued and outstanding 19.99%    
Maximum beneficial percentage hold for conversion of number Of common stock issued and outstanding 5.00%    
Minimum beneficial percentage hold for conversion of number Of common stock issued and outstanding. 5.00%    
BVF Partners L.P [Member] | Exchange Agreement [Member] | Common Shares [Member]      
Share Capital [Line Items]      
Issued (cancelled) pursuant to exchange agreement 2,868,000